PT1699480E - AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO - Google Patents

AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO Download PDF

Info

Publication number
PT1699480E
PT1699480E PT04728317T PT04728317T PT1699480E PT 1699480 E PT1699480 E PT 1699480E PT 04728317 T PT04728317 T PT 04728317T PT 04728317 T PT04728317 T PT 04728317T PT 1699480 E PT1699480 E PT 1699480E
Authority
PT
Portugal
Prior art keywords
therapeutic agent
allogeneic tumor
tumor therapeutic
vaccine
tumor cells
Prior art date
Application number
PT04728317T
Other languages
English (en)
Inventor
Burghardt Wittig
Manuel Schmidt
Tomislav Dobric
Original Assignee
Mologen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologen Ag filed Critical Mologen Ag
Publication of PT1699480E publication Critical patent/PT1699480E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT04728317T 2003-12-30 2004-04-20 AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO PT1699480E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE0304299 2003-12-30

Publications (1)

Publication Number Publication Date
PT1699480E true PT1699480E (pt) 2011-08-30

Family

ID=34716109

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04728317T PT1699480E (pt) 2003-12-30 2004-04-20 AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO

Country Status (12)

Country Link
US (2) US7635468B2 (pt)
EP (1) EP1699480B1 (pt)
JP (1) JP4945247B2 (pt)
CN (3) CN103173460A (pt)
AT (1) ATE512668T1 (pt)
BR (1) BRPI0418157A (pt)
DK (1) DK1699480T3 (pt)
ES (1) ES2366694T3 (pt)
PL (1) PL1699480T3 (pt)
PT (1) PT1699480E (pt)
RU (1) RU2354694C2 (pt)
WO (1) WO2005063280A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1699480E (pt) * 2003-12-30 2011-08-30 Mologen Ag AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO
WO2006015560A1 (de) * 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
EP1922545A1 (de) * 2005-09-08 2008-05-21 Mologen AG Funktioneller in vitro immunassay
BRPI0711607A2 (pt) * 2006-05-11 2012-11-06 Mologen Ag molécula multimérica para modulação da atividade do sistema imunológico humano ou animal, agente de combinação, kit, agente farmacêutico, molécula e uso da mesma
CN101199862B (zh) * 2007-12-19 2011-07-06 北京大学第三医院 B7-1、cd40l质粒混合物
GB2483462A (en) * 2010-09-08 2012-03-14 Mologen Ag Use of a dumbbell-shaped DNA construct for the treatment of cancer through jet-injection administration
GB2523187A (en) * 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
PL3129398T3 (pl) * 2014-04-07 2019-12-31 Lokon Pharma Ab Nowe środki medyczne i ich zastosowanie
WO2016109310A1 (en) 2014-12-31 2016-07-07 Checkmate Pharmaceuticals, Llc Combination tumor immunotherapy
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
EP3436066A1 (en) 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
US10731128B2 (en) 2016-11-22 2020-08-04 Alloplex Biotherapeutics, Inc. Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
US11185586B2 (en) 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
AU2017363256B2 (en) * 2016-11-22 2024-04-18 Alloplex Biotherapeutics Allogeneic tumor cell vaccine
US20210069310A1 (en) * 2018-01-05 2021-03-11 Rolf Jonas Andreas NILSSON Endogenous tumor-derived circular rna and proteins thereof for use as vaccine
JP7511478B2 (ja) 2018-04-09 2024-07-05 チェックメイト ファーマシューティカルズ ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
EP3923979A1 (en) * 2019-02-15 2021-12-22 Rjan Holding AB Autologous cancer tumour associated extrachromosomal circular dna for use as a therapeutic vaccine
AU2020395765A1 (en) 2019-12-03 2022-06-16 Neuvogen, Inc. Tumor cell vaccines

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681562A (en) * 1991-06-25 1997-10-28 Sidney Kimmel Cancer Center Lymphokine gene therapy of cancer
CA2120503C (en) * 1991-10-04 2006-04-04 Glenn Dranoff The regulation of systemic immune responses utilizing cytokines and antigens
DE4416784A1 (de) 1994-05-09 1995-11-30 Soft Gene Gmbh Methode zur Anreicherung von Zellen, die durch ballistischen Transfer modifiziert wurden
DE4431401A1 (de) * 1994-08-24 1996-02-29 Max Delbrueck Centrum Lebendvakzine gegen Tumorerkrankungen
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
DE19746173A1 (de) * 1997-10-18 1999-04-22 Boehringer Ingelheim Int Tumorvakzine
CN1100879C (zh) 1998-02-23 2003-02-05 上海东方肝胆外科医院 多基因转染的细胞株及其构建方法
DE19832840C1 (de) 1998-07-21 2000-06-08 Kerkmann Tucek Aida Mittel zur Immuntherapie von Tumorerkrankungen
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
WO2002060476A2 (de) * 2001-01-31 2002-08-08 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Tumorvakzine
WO2002100345A2 (en) 2001-06-11 2002-12-19 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods of using the same
WO2003031469A2 (de) 2001-10-02 2003-04-17 Mologen Ag Mittel zur verbesserung der immunantwort
WO2003039592A2 (de) * 2001-11-09 2003-05-15 Medigene Aktiengesellschaft Zelluläre impfstoffe mit adjuvanzien
AU2002356763A1 (en) * 2001-11-30 2003-06-10 Medigene Aktiengesellschaft Use of a technically modified cell as a vaccine for treating tumoral disease
WO2004016786A2 (de) 2002-07-19 2004-02-26 Mologen Ag Dna-expressionskonstrukt zur multiplen genexpression
DE10234739A1 (de) 2002-07-30 2004-02-12 Universitätsklinikum Hamburg-Eppendorf Splicing-Variante des humanen p53-Proteins und deren Verwendung zur Herstellung pharmazeutischer Präparate zur Behandlung von Tumorerkrankungen
PT1699480E (pt) * 2003-12-30 2011-08-30 Mologen Ag AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO
US20060165668A1 (en) 2004-12-10 2006-07-27 Liu Linda N Genetically modified tumor cells as cancer vaccines

Also Published As

Publication number Publication date
BRPI0418157A (pt) 2007-04-17
WO2005063280A1 (de) 2005-07-14
EP1699480B1 (de) 2011-06-15
DK1699480T3 (da) 2011-10-10
ES2366694T3 (es) 2011-10-24
US20070160587A1 (en) 2007-07-12
US9345754B2 (en) 2016-05-24
JP2007516985A (ja) 2007-06-28
CN1921882A (zh) 2007-02-28
EP1699480A1 (de) 2006-09-13
CN102994515A (zh) 2013-03-27
US20100297189A1 (en) 2010-11-25
ATE512668T1 (de) 2011-07-15
JP4945247B2 (ja) 2012-06-06
RU2354694C2 (ru) 2009-05-10
CN103173460A (zh) 2013-06-26
RU2006127428A (ru) 2008-02-10
PL1699480T3 (pl) 2011-11-30
US7635468B2 (en) 2009-12-22

Similar Documents

Publication Publication Date Title
PT1699480E (pt) AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO
IL169338A0 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1555955A4 (en) APPLICATION OF THERMOTHERAPY FOR PREVENTING THE GROWTH OF TUMORS
PL374865A1 (en) Treatment of tnf alpha related disorders
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
MY140767A (en) Compounds, methods and compositions
IL207763A (en) Use of placental stem cells and umbilical cord blood to prepare a cure for disease and vulnerability
DE502004003673D1 (de) Biegsame einstechnadel
MY161812A (en) Substituted imidazo ring systems and methods
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
HK1040983A1 (en) Quinones for treatment of diseases.
EP1778186A4 (en) PROCESS FOR PREPARING POLY-ICLC AND USES THEREOF
EP1663377A4 (en) THERAPEUTIC MEDICAL DEVICE, DELIVERY AND METHOD OF USE
SI1140168T1 (en) Vaccination against cancer
WO2004033660A3 (en) Gene expression profiling from ffpe samples
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
DE69734574D1 (de) Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse
AU2003241252A1 (en) New method and composition for producing a cellular allogeneic vaccine
WO2002060476A3 (de) Tumorvakzine
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.